Posted on 18/02/2010 in Pharmaceutical Company Product News Merck Sharpe and Dohme has published new clinical trial data from a study of its human papillomavirus (HPV) treatment Gardasil, which it believes shows its efficacy for both males and females.
The pharmaceutical company conducted a phase III trial to gauge the effectiveness of the treatment in preventing infections and diseases related to the sexually-transmitted condition.
It found that those treated using the drug showed a significantly reduced probability of being afflicted by conditions such as genital warts, anal infections or cancers.
Dr Richard Haupt, executive director at Merck Research Laboratories, expressed satisfaction with the findings, saying: "We are excited to learn more about the potential of Gardasil to help prevent HPV and HPV-related cancers and diseases in both men and women."
The drug, which is also known as Silgard, has already received regulatory approval in almost 120 countries worldwide.
This week, Merck Sharpe and Dohme expressed satisfaction with its financial performance in 2009 after recording a net sales figure of $27.4 billion (17.6 million pounds).Other news stories from 18/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
